WO2008063323A3 - Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof - Google Patents

Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof Download PDF

Info

Publication number
WO2008063323A3
WO2008063323A3 PCT/US2007/021963 US2007021963W WO2008063323A3 WO 2008063323 A3 WO2008063323 A3 WO 2008063323A3 US 2007021963 W US2007021963 W US 2007021963W WO 2008063323 A3 WO2008063323 A3 WO 2008063323A3
Authority
WO
WIPO (PCT)
Prior art keywords
omega
fatty acids
antiarrhythmics
treatment
combination product
Prior art date
Application number
PCT/US2007/021963
Other languages
French (fr)
Other versions
WO2008063323A2 (en
Inventor
George Bobotas
Roelof M L Rongen
Abdel A Fawzy
Ihor Terleckyj
Original Assignee
Reliant Pharmaceuticals Inc
George Bobotas
Roelof M L Rongen
Abdel A Fawzy
Ihor Terleckyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc, George Bobotas, Roelof M L Rongen, Abdel A Fawzy, Ihor Terleckyj filed Critical Reliant Pharmaceuticals Inc
Priority to CA002672876A priority Critical patent/CA2672876A1/en
Priority to EA200970374A priority patent/EA200970374A1/en
Priority to AU2007322291A priority patent/AU2007322291A1/en
Priority to BRPI0719183-9A priority patent/BRPI0719183A2/en
Priority to JP2009532459A priority patent/JP2010506841A/en
Priority to EP07870787A priority patent/EP2083802A2/en
Priority to MX2009003928A priority patent/MX2009003928A/en
Publication of WO2008063323A2 publication Critical patent/WO2008063323A2/en
Publication of WO2008063323A3 publication Critical patent/WO2008063323A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Combinations of one or more antiarrhythmic agents with mixtures of omega-3 fatty acids, methods of administering such combinations, and unit dosages of such combinations.
PCT/US2007/021963 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof WO2008063323A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002672876A CA2672876A1 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
EA200970374A EA200970374A1 (en) 2006-10-13 2007-10-15 TREATMENT WITH ANTIARRHYTHMIC DRUGS AND OMEGA-3 FATTY ACIDS AND THEIR COMBINED PRODUCTS
AU2007322291A AU2007322291A1 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
BRPI0719183-9A BRPI0719183A2 (en) 2006-10-13 2007-10-15 TREATMENT WITH ANTIARRHYTHICS AND FATTY ACIDS OF OMEGA-3 AND A COMBINATION PRODUCT OF THESE
JP2009532459A JP2010506841A (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmic drugs and omega-3 fatty acids and combinations thereof
EP07870787A EP2083802A2 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
MX2009003928A MX2009003928A (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85129406P 2006-10-13 2006-10-13
US60/851,294 2006-10-13

Publications (2)

Publication Number Publication Date
WO2008063323A2 WO2008063323A2 (en) 2008-05-29
WO2008063323A3 true WO2008063323A3 (en) 2008-12-31

Family

ID=39430253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021963 WO2008063323A2 (en) 2006-10-13 2007-10-15 Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof

Country Status (10)

Country Link
EP (1) EP2083802A2 (en)
JP (1) JP2010506841A (en)
KR (1) KR20090086078A (en)
CN (1) CN101557805A (en)
AU (1) AU2007322291A1 (en)
BR (1) BRPI0719183A2 (en)
CA (1) CA2672876A1 (en)
EA (1) EA200970374A1 (en)
MX (1) MX2009003928A (en)
WO (1) WO2008063323A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
PL2323647T3 (en) * 2008-08-07 2015-03-31 Spa Soc Prodotti Antibiotici S P A Long-term treatment of symptomatic heart failure
NZ789295A (en) * 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ627238A (en) * 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
ES2363964B1 (en) 2009-11-20 2012-08-22 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
ES2363965B1 (en) 2009-11-20 2013-01-24 Gp Pharm S.A. CAPSULES OF BETABLOCKING ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
CN102188417A (en) * 2010-03-19 2011-09-21 江苏恒瑞医药股份有限公司 Dronedarone medicinal composition
FR2967067A1 (en) 2010-11-10 2012-05-11 Sanofi Aventis PHARMACEUTICAL COMPOSITION AND GALENIC FORM BASED ON DRONEDARONE AND PROCESS FOR PREPARING THE SAME
EP2755646A4 (en) * 2011-09-15 2015-06-10 Omthera Pharmaceuticals Inc Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
WO2013116738A1 (en) * 2012-02-03 2013-08-08 Cardeus Pharmaceuticals, Inc. Drug formulations
AU2013264518B2 (en) * 2012-05-22 2016-02-11 Kuhnil Pharm. Co., Ltd. Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
TR201503136A2 (en) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of dronedarone and essential fatty acids
WO2017083397A1 (en) * 2015-11-09 2017-05-18 Cayo Max A Cardiac glycosides for the treatment of hypercholesterolemia
WO2017139757A1 (en) * 2016-02-12 2017-08-17 The General Hospital Corporation Targeting macrophages to modulate electrical conduction in the heart
DK3618847T3 (en) 2017-05-05 2021-05-25 Boston Medical Ct Corp GAP junction modulators of intercellular communication and their use in the treatment of diabetic eye disease
US20210030733A1 (en) * 2018-04-16 2021-02-04 Alsar Ltd Partnership Compositions and methods for sustained release of flecainide
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0429928A (en) * 1990-05-25 1992-01-31 Nippon Oil & Fats Co Ltd Antiarrhythmic agent
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
WO2003017774A1 (en) * 2001-08-22 2003-03-06 Isis Innovation Limited Palatable high fat composition
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0429928A (en) * 1990-05-25 1992-01-31 Nippon Oil & Fats Co Ltd Antiarrhythmic agent
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
WO2003017774A1 (en) * 2001-08-22 2003-03-06 Isis Innovation Limited Palatable high fat composition
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils

Also Published As

Publication number Publication date
JP2010506841A (en) 2010-03-04
EP2083802A2 (en) 2009-08-05
MX2009003928A (en) 2009-09-21
CA2672876A1 (en) 2008-05-29
CN101557805A (en) 2009-10-14
AU2007322291A1 (en) 2008-05-29
BRPI0719183A2 (en) 2014-06-03
KR20090086078A (en) 2009-08-10
EA200970374A1 (en) 2009-10-30
WO2008063323A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008063323A3 (en) Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
WO2007011886A3 (en) Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
WO2007016256A3 (en) Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
EP1861087A4 (en) Treatment with statin and omega-3 fatty acids and a combination product thereof
EP2518079A3 (en) HCV/HIV inhibitors and their uses
CA118474S (en) Wall-mountable lighting control unit
CA118472S (en) Wall-mountable lighting control unit
CA118468S (en) Wall-mountable lighting control unit
CA118470S (en) Wall-mountable lighting control unit
CA118471S (en) Wall-mountable lighting control unit
CA118467S (en) Wall-mountable lighting control unit
CA118473S (en) Wall-mountable lighting control unit
CA118469S (en) Wall-mountable lighting control unit
CA118466S (en) Wall-mountable lighting control unit
WO2007146411A3 (en) Nanoshell therapy
SI2044076T1 (en) Process for the preparation of asenapine and intermediate products used in said process.
WO2007088062A3 (en) Food product comprising a proline specific protease
CA119221S (en) Blister package
CA118314S (en) Dispensing pump head
IL195176A0 (en) 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments
EP1954254A4 (en) Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
CL2007003718A1 (en) MACROCICLOS COMPOUNDS, SELECTIVE INHIBITORS OF SERIOAPROTEASA VIEW COAGULATION FACTOR; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF A THROMBOEMBOLIC DISORDER.
ATE511765T1 (en) FLAVORING FRACTIONED TOMATO EXTRACT AND COMPOSITIONS CONTAINING THE SAME
USD560171S1 (en) Switch
CA117526S (en) Confectionery product dispensing package

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780046090.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07870787

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007322291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2672876

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009532459

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/003928

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2838/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007322291

Country of ref document: AU

Date of ref document: 20071015

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007870787

Country of ref document: EP

Ref document number: 200970374

Country of ref document: EA

Ref document number: 1020097009699

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0719183

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090413